Efeito dos ácidos graxos na síndrome metabólica: papel do ômega 3.

Abstract

Metabolic Syndrome (MS) can be defined as a group of interrelated risk factors of metabolic origin that may contribute to the development of cardiovascular disease (CVD) and / or Type 2 diabetes mellitus. Metabolic risk factors include atherogenic dyslipidemia (hypertriglyceridemia, elevated apolipoprotein B levels, small and dense LDL-cholesterol particles, and low levels of HDL-cholesterol), hypertension, hyperglycemia, and a pro-inflammatory and prothrombotic state. This syndrome reaches the world population in large part, making it a more critical look for this pathology. The present study seeks to emphasize the importance of omega-3 fatty acids in the therapy of this disease, since it is known that the use of the same provides benefits to human health. The study is characterized as a systematic bibliographic research. The data were obtained in the months of April and May of 2019 in a systematic way, starting from database like Medline, Pubmed, Lilacs, Scielo, Google Scholar and the national and international committees of health, prioritizing published matters in the annual band of 2014 to 2019, in which a systematic review of the literature. Through the review it was possible to identify that MS is directly related to chronic noncommunicable diseases (DCNT) and CVD and that omega-3 has great potential to soften SM symptoms. The study concluded that despite the need for more studies on the subject, it was evident that the consumption of omega-3s linked to a change in healthy habits is beneficial for the treatment, but also for the prophylaxis of MS.